No abstract

No abstract

Patientswere monitored for perioperative complications. Results One hundred patients underwent ablation with 25 cases conducted in each arm. Complete PVI was attained in all study subjects. For the vHPSD group, PVI procedural duration, ablation and fluoroscopy times were 71.7 ± 6.35 min, 9.21 ± 0.76 min and 15.1 ± 1.50 min respectively. The HSPD group exhibited total PVI, burn and fluoroscopy times of 90. 2 ± 5.59 min (p=0.03), 10.3 ± 2.40 min (p<0.0001) and 34.1 ± 1.67 min (p=0.1) respectively. In comparison, the PCRF group exhibited longer procedure duration, ablation and fluoroscopy times of 93.3 ± 6.50 min (p=0.01), 15.2 ± 1.73 min (p<0.0001), 37.8 ± 2.47 min (p=0.870). Whereas procedural and fluoroscopy times of 96.3 ± 7.1 min (p=0.01) and 18.8 ± 1.31 (p=0.05) were observed in the cryo-ablation group. Procedural doses of morphine and midazolam for the vHPSD, Qmode, PCRF and CRYO group were 11.3 mg + 4.00 mg, 15.5 mg (p=0.0003) + 9.33 mg (p=0.0003), 15.7 mg (p=0.0002) + 8.03 mg (p=0.02), and 8.19 mg (p=0.01) + 4.84 mg (p=0.303) respectively. No adverse procedural events were recorded for the vHPSD while 2 pericardial effusions occurred in the PCRF group, 1 cardiac tamponade in the Qmode group and 2 transient ischaemic attacks in the CRYO group. Conclusion With the emergence of vHPSD RF ablation, preliminary findings indicate significant potential in reduction of procedural and ablation time. Further analysis is ongoing in order to ascertain longer-term efficacy and patient safety. Conflict of Interest None to declare 112 AMIODARONE FOLLOW-UP IN 'TRACKER CLINIC'